GenEditBio and ToolGen strike cross-license deal to advance next-generation in vivo genome-editing therapies
The agreement combines ToolGen’s CRISPR-Cas9 platform with GenEditBio’s LNP delivery technology to accelerate development of once-and-done genome-editing treatments